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Abstract
Background: The emergence of antibiotic resistant pathogenic bacteria has reduced our ability to combat
infectious diseases. At the same time the numbers of new antibiotics reaching the market have decreased. This
situation has created an urgent need to discover novel antibiotic scaffolds. Recently, the application of pattern
recognition techniques to identify molecular fingerprints in ‘omics’ studies, has emerged as an important tool in
biomedical research and laboratory medicine to identify pathogens, to monitor therapeutic treatments or to
develop drugs with improved metabolic stability, toxicological profile and efficacy. Here, we hypothesize that a
combination of metabolic intracellular fingerprints and extracellular footprints would provide a more
comprehensive picture about the mechanism of action of novel antibiotics in drug discovery programs.
Results: In an attempt to integrate the metabolomics approach as a classification tool in the drug discovery processes,
we have used quantitative 1H NMR spectroscopy to study the metabolic response of Escherichia coli cultures to different
antibiotics. Within the frame of our study the effects of five different and well-known antibiotic classes on the bacterial
metabolome were investigated both by intracellular fingerprint and extracellular footprint analysis. The metabolic
fingerprints and footprints of bacterial cultures were affected in a distinct manner and provided complementary
information regarding intracellular and extracellular targets such as protein synthesis, DNA and cell wall. While cell cultures
affected by antibiotics that act on intracellular targets showed class-specific fingerprints, the metabolic footprints differed
significantly only when antibiotics that target the cell wall were applied. In addition, using a training set of E. coli
fingerprints extracted after treatment with different antibiotic classes, the mode of action of streptomycin, tetracycline and
carbenicillin could be correctly predicted.
Conclusion: The metabolic profiles of E. coli treated with antibiotics with intracellular and extracellular targets could
be separated in fingerprint and footprint analysis, respectively and provided complementary information. Based on
the specific fingerprints obtained for different classes of antibiotics, the mode of action of several antibiotics could be
predicted. The same classification approach should be applicable to studies of other pathogenic bacteria.
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Background
The number of bacterial infectious disease outbreaks that
are caused by Gram-positive and Gram-negative patho-
gens has increased tremendously over the past decade [1].
In particular, the increasing spread of bacterial resistance
to commonly used antimicrobials has led to a significant
threat in hospital as well as in community settings [2, 3].
Genetic alterations, caused by exchange of genetic material
with other organisms or through mutagenesis of its own
DNA, allow bacteria to overcome the action of many anti-
biotics [4]. Clinically important examples such as vanco-
mycin resistance among enterococci, methicillin-resistant
staphylococci, multiple resistant pneumococci and
streptococci as well as multi- and pan-drug resistant
Gram-negatives are increasingly being encountered in
clinical settings. However, at the same time the market
for research and development of new antibiotics in the
pharmaceutical industry has largely evaporated [5–7].
Over the years, antibacterial drug-target interactions of
the presently used antibiotics have been intensely studied,
and it is well-known that these agents can inhibit various
essential cellular functions such as cell wall biosynthesis,
DNA supercoiling, transcription, translation, or folate bio-
synthesis [8, 9]. For many years, the development of resist-
ance could be partly compensated by the synthesis of
novel analogues of existing compounds. However, such
chemical modifications are finite and to keep pace with
the remarkable adaptability of the bacteria and to com-
bat the prevalence of multi-drug-resistant pathogens,
novel antibiotics that target distinct cellular functions are
needed [10]. Consequently the focus in the drug discovery
processes has moved from introducing structural varia-
tions in existing classes of antibiotics to target-based or
whole cell-based high-throughput screening (HTS) of
large chemical libraries in order to identify novel “hits” [6,
11, 12]. Unfortunately, these strategies have not yet led to
any major successes so far [13, 14]. On the one hand,
“hits” from target-based in vitro assays often turned out
not to penetrate the bacterial cell and hence difficulties
arose when correlating the outcome of enzymatic inhib-
ition studies with their in vivo antimicrobial effects [11,
15]. On the other hand, in whole cell based HTS, most of
the established methods for the assessment of the anti-
microbial efficiency of compounds such as the broth
microdilution, and the disk diffusion methods have the
disadvantage of being time consuming [16–18]. Even
when a HTS “hit” is identified, a series of drug develop-
ment procedures is required to optimize the activity and
characterize the selectivity and toxicity of novel com-
pounds [11, 19].
In recent years further efforts have been spent using
proteomic, genomic and metabolomic approaches to study
the cellular processes and their responses to special anti-
biotic stimuli as well as potential targets [20–24]. These
approaches demand a departure from the current drug
discovery strategies which typically follow a linear process
of identification, evaluation and refinement towards a more
integrated parallel process [25]. Metabolomics in particular
offers a unique strategy to detect metabolic changes that
occur in an organism in response to drugs and the outcome
of such studies can provide insights into their correspond-
ing mode of action [26, 27]. In addition, different physico-
chemical methods such as mass spectrometry [28, 29], FT-
IR spectroscopy [30], Raman microspectroscopy [31–33]
and NMR spectroscopy [27, 34] have already been devel-
oped for metabolic or whole-organism profiling of the
microbial response to antibiotics. In metabolomics the
investigations carried out so far have focused on studying
changes in the intracellular metabolism in response to anti-
bacterial compounds. We hypothesize that a combination
of intracellular fingerprinting and extracellular footprinting
metabolomics approaches would give rise to a more
complete mechanistic insight. To evaluate this notion, we
have used 1H NMR to analyze metabolic changes in bacter-
ial extracts and in the extracellular culture medium from
Escherichia coli cultures following antibiotic treatments.
Specifically, we have studied the effect of various antibiotics
with different mechanisms of action to determine if the
metabolomics approach can be used as a potential classifi-
cation tool.
Our results show that the metabolic finger- and foot-
prints of bacterial cultures are affected in a distinct manner
by antibiotic treatments and that they provide complemen-
tary information about intra- and extracellular modes of
action. Clusters of antibiotics that target intracellular pro-
cesses could be separated in the fingerprint analysis. In
contrast, the metabolic footprints provided distinct profiles
for antibiotics that inhibit cell wall biosynthesis. Finally, we
incorporated our metabolic profiling data in one descrip-
tive model and in doing so we could predict the mode of
action of several antibiotics that had not been included in
the original training set.
Results
Antimicrobial susceptibility of E. coli
In this work we have investigated the antimicrobial effect
of nine antibiotics which belong to five different classes of
antibiotics with different modes of action (Table 1). The
MIC (minimum inhibitory concentration) values were
determined for E. coli for all antibiotics in defined medium
to characterize their antimicrobial susceptibility (Table 2).
For reliable metabolite identification and quantification in
the subsequent metabolomics study, a defined minimal
medium was necessary to limit the presence of overlap-
ping signals in the 1H NMR-spectra caused by the pleth-
ora of nutrients that are present in rich media. The
different antibiotics showed MIC values ranging between
0.4 and 12.5 μM. Since the MIC value is defined as the
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lowest concentration of an antibiotic that inhibits the vis-
ible growth of a microorganism after overnight incubation,
a concentration of 100 μM was applied for the culture
experiments in the metabolomics study which is in ac-
cordance with standard guidelines for cytotoxicity assays
[35, 36]. Our goal was to cause a rapid reduction in the
bacterial growth rate but not to inhibit the bacterial
growth completely or to induce bacterial cell death during
the period of antibiotic exposure. To adjust the required
incubation time, bacterial cultures were grown in the
exponential growth phase to an OD600 (optical density at
600 nm) of 0.6 and aliquots were then exposed to the anti-
biotics in a concentration of 100 μM as well as to the
corresponding solvents as controls. Except for cefalexin,
ciprofloxacin and ofloxacin which were dissolved in an
acidic aqueous vehicle, all antibiotics were dissolved in
H2O (Table 2). These subcultures were tested spectro-
scopically after 15, 30, 60 and 120 min of incubation
(Fig. 1a). Control samples reached the stationary phase of
the growth curve after 120 min of incubation. Both for
bacteriostatic and bactericidal antibiotics, an incubation
time of 30 min already resulted in an inhibition of cell
growth. Corresponding CFU (colony forming units)
counts confirmed that the drug exposure was below lethal
levels (Fig. 1b) and all bacterial cultures treated with anti-
biotics showed a survival rate of approximately 100 %
compared to untreated cultures. In contrast, growth curves
of bacteria exposed to bactericidal antibiotics that affect the
cell wall (ampicillin, carbenicillin, and cefalexin) showed
significantly decreased OD values after an incubation time
of 60 min, indicating progressive cell lysis. Taken together
the optimized experimental conditions to investigate
the antibiotic effect on E. coli cultures by intra- and
extracellular finger- and footprint analysis were identi-
fied after 30 min of antibiotic treatment at a concentra-
tion of 100 μM.
To investigate the impact of different solvents on the
intra- and extracellular metabolic profiles of E. coli, samples
of bacterial cell extracts and of the extracellular medium
were prepared after 30 min of treatment with 1 % of the
following commonly used solvents and solubilizers: H2O,
an acidic aqueous solution at pH 1.5 and DMSO. It is well
known that DMSO has cytotoxic properties, however, as it
is often used as standard solvent for natural plant com-
pounds in screening assays for antimicrobial or antiproto-
zoal characteristics, we also analyzed its influence on the
metabolic fingerprint and footprint, using PLS-DA (Partial
Least Squares Discriminant Analysis). Two compo-
nents of the statistical analysis encapsulated 97 and
81 % of the interclass variation (R2) with a corre-
sponding cross-validation accuracy (Q2) of 91 and
30 % for finger- and footprints, respectively. Results
showed that the lower pH of the acidic aqueous solu-
tion did not affect the intra- or extracellular metabol-
ite composition at this low concentration. However in
cell extracts obtained after the treatment with 1 %
DMSO, significant changes in the metabolic profiles
became visible (Fig. 2a, b). Thus, only antibiotics sol-
uble in aqueous solvents were included in our study
(Table 2).
Bacterial metabolic finger- and footprinting
Ampicillin, cefalexin, doxycycline, ciprofloxacin and kana-
mycin are five antibiotics with different modes of action
(Table 1). Ampicillin and cefalexin affect cell wall biosyn-
thesis, doxycycline and kanamycin inhibit intracellular
protein synthesis while ciprofloxacin inhibits DNA syn-
thesis. To examine the metabolic effect of these antibiotics
on E. coli, 1H NMR metabolite profiles of cell extracts
were compared to those of controls treated with solvent
(Fig. 3a, b). PLS-DA of the metabolic fingerprint profiles
(Fig. 3a) resulted in a R2 and Q2 value of 76 and 65 % re-
spectively for the first three components. Antibiotics with
intracellular and extracellular modes of action were clearly
separated along the first component which explained 32 %
of the total variation. Antibiotics with different intracellu-
lar targets could be clearly separated from each other in
different clusters. Comparison between 1H NMR-spectra
of cell extracts derived from different intracellular targeted
antibiotics showed changed levels of alanine, glutamate,
Table 1 Mode of action of different classes of antibiotics
Mode of action Action Antibiotics
Cell wall synthesis inhibitors:

















Inhibition of 30s subunit
bactericidal Aminoglycosides
Kanamycin, Streptomycin
Table 2 MIC values [μM] of different antibiotics







Cefalexin H2O-pH 1.5 0.6
Ciprofloxacin H2O-pH 1.5 0.4
Ofloxacin H2O-pH 1.5 0.4
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Fig. 1 Antibiotic effect on E. coli. a OD curves and b CFU counts of E. coli cultures exposed to solvents and antibiotics with bacteriostatic, bactericidal and
cell wall affecting mode of action in a concentration of 100 μM. Antibiotics affecting the cell wall resulted in significantly decreased OD values indicating
that a substantial amount of cells were lysed over time course. After an incubation time of 30 min normal CFU counts were obtained for all antibiotics
Fig. 2 Effect of different solvents on metabolic fingerprints and footprints derived from E. coli cultures. a PLS-DA scores plot (2 components, R2 = 0.97, Q2
= 0.91) of intracellular metabolic profiles of E. coli cultures after incubation with different solvents (H2O, H2O_pH1.5, DMSO) in a concentration of 1 % for
30 min. b PLS-DA scores plot (2 components, R2 = 0.81, Q2 = 0.30) of corresponding footprints. N = 6 for each solvent
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acetamide as well as of energy metabolites such as etha-
nol, citrate, formate and isobutyrate (Fig. 4a, b). Based on
the results of the corresponding PLS-DA, significantly
increased and decreased levels of amino acids (Fig. 4c), en-
ergy metabolites (Fig. 4d) and stress induced metabolites
(Fig. 4e) could additionally be identified and quantified. In
contrast to antibiotics with intracellular mode of action,
the effects of cell wall inhibitors on the metabolic finger-
print profiles were less pronounced and antibiotic profiles
were similar to those of controls (Fig. 3a; b, 5 components,
R2 = 0.88, Q2 = 0.49).
To gain more insight into the metabolic effects caused
by antibiotics with different antimicrobial modes of action,
extracellular metabolic footprints obtained after antibiotic
treatment were also statistically investigated by using a
seven component PLS-DA model with a R2 and Q2 value
of 72 and 48 % respectively (Fig. 3c). While the metabolo-
mic profiles derived from antibiotics with an intracellular
mode of action, such as ciprofloxacin, doxycycline and
kanamycin could be differentiated from controls, the
magnitude and significance of the separation was much
smaller than that for the cell wall affecting clusters of
ampicillin and cefalexin. For those profiles, most of the
TCA (tricarboxylic acid) energy metabolites were de-
creased while metabolites derived from anaerobic energy
pathways such as formate, acetate, and acetone were in-
creased. Noticeable changes of specific amino acids and
precursors in clusters of ampicillin and cefalexin are pre-
sented in Fig. 4f. Taken together, while metabolic finger-
print profiles extracted after treatment with antibiotics
with different intracellular targets could be clearly sepa-
rated from each other, metabolic footprints were necessary
to differentiate cell wall affecting antibiotics.
Cell wall affecting antibiotics analyzed by FACS and
fluorescence microscopy
To better understand the metabolic changes, we character-
ized the permeability of the bacterial membrane by staining
the bacteria with SYTO9 and propidium iodide (PI) after
incubation with different antibiotics. SYTO9, which is
membrane permeant, generally labels all bacteria in a popu-
lation with a green fluorescence. In contrast, propidium
iodide, characterized by its red fluorescence, is excluded by
healthy cells due to membrane impermeability. In dead
bacterial cells, both the displacement of SYTO9 by propi-
dium iodide due to the stronger affinity of the latter for
nucleic acids and the quenching of SYTO9 emission by
fluorescence resonance energy transfer (FRET) is respon-
sible for the replacement of the green fluorescence with the
red one [37, 38]. The fluorescent bacteria were then quanti-
fied by flow cytometry (fluorescence-activated cell sorting,
FACS; Fig. 5a, b) and visualized by fluorescence microscopy
(Fig. 6a, b). Bacterial samples that had been incubated with
cell wall affecting antibiotics such as ampicillin, carbenicil-
lin, and cefalexin showed reduced membrane integrity,
which allowed propidium iodide to cross the membrane
and resulted in a significant increase in SYTO9/PI double
stained population after 45 min (Fig. 5b). CFU counts in
contrast were still unaffected after an antimicrobial incuba-
tion time of 30 min (Fig. 1b). A comparison of the corre-
sponding dot plots of FSC (Forward SCatter) vs SSC (Side
SCatter) for E. coli in the various antibiotics is shown in
Fig. 5a. All cell wall affecting antibiotic samples displayed
an increase in population outside the P1 gate where intact
population of E. coli cells is located. Fluorescence micros-
copy confirmed the presence of a red fluorescent bacterial
population already 15 min post incubation with ampicillin;
these cells also showed the first signs of cell debris after an
incubation time of 30 and 45 min in contrast to the control
or samples treated with intracellular targeting antibiotics
such as streptomycin (Fig. 6a, b).
Prediction of antibiotic mode of action by fingerprint
analysis
A six component PLS-DA model, based on the intracellular
metabolite profiles obtained for doxycycline, kanamycin,
Fig. 3 Multivariate statistical analysis of metabolic fingerprints and footprints derived from E. coli cultures after antibiotic treatment. a PLS-DA
scores plot (3 components, R2 = 0.76, Q2 = 0.65) of intracellular metabolic profiles of E. coli cultures after incubation with antibiotics with
intra- (ciprofloxacin, kanamycin, doxycycline) and extracellular (ampicillin, cefalexin) action for 30 min. b PLS-DA scores plot (5 components, R2 =
0.88, Q2 = 0.49) of fingerprints treated with ampicillin and cefalexin compared to controls and c PLS-DA scores plot of footprints corresponding
to a (7 components, R2 = 0.72, Q2 = 0.48). N = 6 for each compound
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Fig. 4 (See legend on next page.)
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and control cells, was built to predict the response of E. coli
to treatments with streptomycin, tetracycline, and
carbenicillin (Fig. 7). The model showed a R2 and Q2 value
of 99 and 90 % respectively. The degree of similarity was
used to predict the likelihood of each of the latter having a
similar mode of action to one of the former (doxycycline
and tetracycline; kanamycin and streptomycin; carbenicillin
as cell wall affecting antibiotic similar to the control). The
probabilities that the fingerprints of streptomycin, tetracyc-
line and carbenicillin belong to one of the clusters of doxy-
cycline, kanamycin or of the control is summarized in
Table 3. A 88.7 % prediction was calculated that the finger-
print of streptomycin is similar to that of kanamycin. The
group of tetracycline showed 76.4 % probability of being
similar to the profiles of doxycycline, and the fingerprint of
carbenicillin matched those of the control with a probability
of 62.1 %. In each case, the highest probability was assigned
to the training class with the same known mode of action
or in the case of carbenicillin with that of the control. The
similarity of the response can be visualized by comparing
the predicted scores of the test samples to those of the
training samples (Fig. 7).
Discussion
Increasing evidence suggests that metabolomics can be a
useful tool to describe the mode of action of different anti-
biotics thereby driving drug discovery strategies in a more
integrated parallel process of identification, evaluation and
refinement [25]. Recently, it was shown that the metabolic
fingerprints of bacteria affected by antibiotics with similar
mode of action cluster together in statistical pattern recog-
nition analysis [34]. In our study we investigated nine anti-
biotics which belong to five different antibiotic classes
(Table 1) both by fingerprint and footprint analysis. System-
atically, we studied the antibiotic effects on the cellular
metabolism. Our results showed that metabolic fingerprints
and footprints tell us different stories about antibiotics with
intracellular targets and those affecting the bacterial cell
wall. While antibiotics with intracellular targets showed
specific fingerprints for different modes of action, cell wall
affecting antibiotics induced fingerprints similar to those of
control cultures and could only be separated and charac-
terized by their corresponding footprints. Ciprofloxacin,
affecting DNA supercoiling, as well as kanamycin and
doxycycline, both affecting protein synthesis by different
mechanisms, differed in their fingerprints significantly
from control samples and cell wall inhibitors in the first
and second component (Fig. 3a). Distinct amino acid
levels were found after kanamycin and doxycycline treat-
ment which might be a consequence of the inhibition of
different protein synthesis pathways while ciprofloxacin
mainly led to signs of general stress response showing
high concentrations in betaine and glutamate [39–41]
(Fig. 4c, d, e). The unique effect of antibiotics on the intra-
cellular bacterial metabolism allowed us to distinguish
between the different classes of antibiotics that act within
the cell. In contrast, the corresponding footprints showed
similarities in a wide range of metabolites for bactericidal
antibiotics with intracellular targets but differed signifi-
cantly for cell wall affecting antibiotics as well as for bac-
teriostatic doxycycline (Fig. 3c). All cell wall perturbing
antibiotics such as ampicillin, carbenicillin and cefalexin
showed enhanced membrane permeability, indicating that
membrane perturbation might result in intracellular me-
tabolite leaking. This hypothesis was confirmed by the
observation of cell debris in the scatter plots (Fig. 5a) and
the visualization of cells with different shape and mem-
brane integrity by fluorescence microscopy. Since bacteria
of the doxycycline treated group did not show altered
membrane permeability but revealed significant changes
in both finger- and footprints, it is plausible that metabol-
ite changes in the extracellular medium are also caused by
active metabolite release. The mode of action of doxycyc-
line is based on a bacteriostatic effect which might add-
itionally result in an active release of metabolites in the
environment.
The proof of concept to use metabolomics as a powerful
tool to classify antibiotics according to their different modes
of action could be strengthened by predicting the class
membership of antibiotics which belonged to different and
known antibiotic classes, e.g. to the class of tetracyclines
(tetracycline), the class of aminoglycosides (streptomycin)
and the class of ß-lactam-antibiotics (carbenicillin) (Fig. 7).
Nonetheless, the use of metabolomics as a classification
tool for antibiotics with different modes of action is still in
its infancy. Our study was restricted to antibiotics that were
soluble in aqueous solutions. The high sensitivity of the
method makes the use of different solvents a critical issue.
Since the different chemical characteristics of novel and
customary antibiotics often require the use of different
solvents [36], the effect of the vehicle on the metabolomic
profile might mask differences caused by different antibiotic
classes (Fig. 2a, b). Even final solvent concentrations
between 0.5 to 1 % in the bacterial culture which do not
show any effects in standard cytotoxicity assays such as disk
diffusion assays [42] can have a significant impact on the
(See figure on previous page.)
Fig. 4 Qualitative and quantitative differences between 1H NMR spectra acquired from E. coli cultures after antibiotic treatment. a + b Noticeable
metabolite changes in fingerprints after treatment with doxycycline, kanamycin and ciprofloxacin. Bar charts showing metabolite levels of important
significantly increased and decreased intracellular c amino acids, d energy metabolites and e stress induced metabolites (* < p = 0.05). f Noticeable
metabolite changes in footprints after treatment with cefalexin and ampicillin
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Fig. 5 (See legend on next page.)
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Fig. 5 Cell wall permeability of E. coli after antibiotic treatment investigated by FACS. Flow cytometry measurements a+b of E. coli cultures stained with
Syto 9 and propidium iodide (PI) after incubation with different antibiotics. a Forward scatter (FSC) vs Side scatter (SSC) dot plot of population of E. coli
cells at 30 min time point. b Ratio of E. coli populations stained with propidium iodide and SYTO 9 alone post 5, 15, 30 and 45 min antibiotic treatment
Fig. 6 Cell wall permeability of E. coli after antibiotic treatment investigated by fluorescence microscopy. Fluorescence microscopy of E. coli
cultures incubated with streptomycin a and ampicillin b for 5, 15, 30 and 45 min and stained with SYTO9 and propidium iodide (PI). SYTO9 is
membrane permeant and generally labels all bacteria in a population with a green fluorescence. PI is characterized by its red fluorescence and
replaces the green fluorescence in cells with reduced membrane impermeability. Images after ampicillin treatment showed increased signs of cell
debris in the red fluorescence channel at 30 and 45 min time point compared to samples after streptomycin treatment
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bacterial metabolism and thus make the comparison of dif-
ferent chemical classes difficult, as our example of DMSO
showed. Also the antibiotic effect might be enhanced and
might not correlate with the actual mode of action any
more. One possibility would be to add DMSO in the cul-
ture medium in all experiments.
Conclusions
In conclusion, in this pilot study we have shown that the
finger- and footprint metabolite profiles of bacterial extracts
from cells exposed to antibiotics can be separated based on
their mode of action, and provide complementary informa-
tion about intra- and extracellular processes. This orthog-
onal information content underscores the importance of
examining two different compartments - intra- and extra-
cellular - to obtain a more complete picture of antibiotic
modes of action, and lays bare the problems which can
arise when studies assume footprint profiles reflect
internal changes in biochemistry. Nevertheless, in the
proper context metabolic finger- and footprint profiles
may be able to identify the mechanism of action of novel
antibiotics. However, to better define the metabolic differ-
ences associated with different mechanisms of antibiotic
action including differences between bacteriostatic and
bactericidal action, a larger study will be necessary. To this
end, the effect of additional intracellular acting antibiotics
as well as multiple antibiotics that belong to the same
class will be investigated on different clinical bacterial iso-
lates in the future.
Methods
Bacteria and growth conditions
Bacterial strains
Experiments were performed on the Gram-negative bacter-
ial strain of Escherichia coli K12 BL21 (DE3) with the geno-
type: F– ompT hsdSB(rB–mB–) gal dcm (DE3).
Cultivation
Prior to analysis, frozen stock suspensions of bacteria were
cultured overnight in 5 ml of Luria-Bertani (LB) medium at
37 °C with shaking at 200 rpm. For the bacterial foot- and
fingerprint analysis, 1 ml of the overnight culture was re-
inoculated in 50 ml of a defined medium (900 ml H20,
100 ml 10 x salt stock solution and addition of 3 g glucose,
1 g NH4Cl, 1 ml vitamins, 4 μl x 10 mM CuSO4, 4 μl x
10 mM MnCl2, 4 μl x 10 mM ZnSO4, 10 μl x 1 M CaCl2,
2 ml x 1 mM FeSO4, 4 ml x 1 M MgSO4). 1 l of the 10 x
salt solution contained: 60 g Na2HPO4, 30 g KH2PO4 and
Fig. 7 Prediction of the antibiotic mode of action. PLS-DA scores plot of fingerprints of E. coli cultures incubated with a doxycycline, kanamycin and
H2O for 30 min (6 components, R2 = 0.99, Q2 = 0.90). Using this model as reference data set fingerprints of cultures incubated with b tetracycline, c
streptomycin and d carbenicillin were predicted according to their mode of action. Tetracycline and doxycycline resulted in similar fingerprints as well
as kanamycin and streptomycin. Carbenicillin, an antibiotic which inhibits the cell wall showed strong similarities to the control group. N = 6 for
each compound
Table 3 Prediction of mechanisms of action of tetracycline,
streptomycin and carbenicillin
Tetracycline Streptomycin Carbenicillin
H2O [%] −2.27 ± 14.08 5.30 ± 16.65 62.13 ± 24.50
Doxycycline [%] 76.42 ± 25.84 5.96 ± 10.57 −6.29 ± 14.71
Kanamycin [%] 25.85 ± 37.39 88.74 ± 25.37 44.16 ± 11.17
Calculations based on fingerprints extracted from exposed E. coli cultures
using a reference data set of samples treated with H2O, doxycycline
and kanamycin
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5 g NaCl. Subsequently the culture was grown up to an
OD600 (optical density at 600 nm) of 0.6 and was used for
antibiotic treatment and cytotoxicity assays.
Antibiotics and stock solutions
Antibiotics: ampicillin sodium, carbenicillin disodium,
tetracycline, doxycycline hyclate, kanamycin sulfate,
streptomycin sulfate, ofloxacin, cefalexin, ciprofloxacine
were purchased from Sigma Aldrich, Oakville, Ontario,
Canada.
Antibiotic stock solutions: All antibiotics were dissolved
to yield a stock solution of 10 mM. Ampicillin, carbenicillin,
tetracycline, doxycycline, kanamycin, streptomycin were
dissolved in distilled H2O (pH = 6.5); ofloxacin, ciprofloxa-




The assay standardized by the DIN 58940–8 guideline [35]
was performed under modified conditions. In microtiter
plates, 100 μL of the exponential phase cultures adjusted to
a cell density of 2 × 107 cells/mL (1:10 dilution of a bacter-
ial culture at an OD600 of 0.6) were incubated with 100 μL
of 2-fold serially diluted antimicrobial agents in the defined
minimal culture medium at 37 °C for 24 h. The dilution
series was in the range of 100 μM and 100 pM. The MIC,
determined by microplate reader at 550 nm (n = 3), was
regarded as the lowest antibiotic concentration where
growth of the bacteria after 24 h incubation was inhibited.
OD600
50 ml of E. coli cultures at an OD600 of 0.6 were exposed
to different antibiotics in a concentration of 100 μM. After
0, 30, 60 and 120 min of incubation an aliquote was taken
and the corresponding OD value was measured at 600 nm
(n = 3).
CFU counts
1 ml of the 50 ml bacterial culture at an OD600 of 0.6
was aliquoted into 15 ml culture tubes and exposed to
different antibiotics in a concentration of 100 μM for 5,
15 and 30 min.
The corresponding viable cell concentration after treat-
ment was determined by counting the CFUs. Therefore, a
bacterial sample was serially diluted and a known volume
was plated onto LB agar. The cell concentration resulted
from counting the colonies that had formed and was calcu-
lated relatively to a control sample without antibiotic treat-
ment (n = 3).
FACS and fluorescence microscopy
1 ml of the 50 ml bacterial culture at OD600 of 0.6 was ali-
quoted into 15 ml culture tubes and exposed to different
antibiotics at a concentration of 100 μM for 5, 15, 30 and
45 min. To each time point, the cell aliquot was washed
with PBS, stained with SYTO9 and propidium iodide life
dead marker and analyzed by FACS or fluorescence micros-
copy (n = 2).
Fluorescent staining
To 1 ml of the bacterial aliquot suspended in PBS an
amount of 1 μl of both 0.33 mM SYTO9 and 10 mM pro-
pidium iodide was added for fluorescent labeling. After an
incubation time of 15 min in the dark, the samples were
investigated by FACS or fluorescence microscopy.
Flow cytometry analysis
Flow cytometry experiments were conducted on a BD
Biosciences LSRII cytometer controlled by BD FACSDiva
software. SYTO9 excitation was performed with a 488 nm
laser and fluorescence emission detected with a 525/50 nm
band pass filter. Green laser at 532 nm was used to excite
propidium iodide and fluorescence emission was captured
with a 610/20 nm band pass filter. Data analysis was done
using FACSDiva software, Flowjo (Tree Star, Inc).
Fluorescence microscopy
Fluorescence microscopy was performed using an LSM 780
(Zeiss, Jena, Germany) confocal laser scanning microscope
equipped with a 20x/0.8 Plan-Apochromate Objective and
a photomultiplier tube as detector. For excitation, the
following lasers were used: an argon laser with 488 nm
wavelength and power of 0.05 mW for excitation of SYTO9
fluorescence and a diode-pumped solid-state laser with
561 nm wavelength and power of 0.2 mW for excitation of
PI fluorescence. Fluorescence emission was detected in the
range of 493 to 592 nm with a detector gain of 630 for
SYTO9 and in the range of 566 to 718 nm with a detector
gain of 650 for PI. The Pinhole diameter was set to 32 μm
for SYTO9 and to 38 μm for PI detection, respectively.
Scans were recorded subsequently as two separate tracks to
avoid cross-talk of laser excitation. Scanning time was kept
short by using a pixel dwell time of 1.58 μs, and 8-bit
images of 512 × 512 pixel were generated. For figure prep-
aration and visualisation, the images were cropped to 256 ×
256 pixel and the contrast and brightness for SYTO9 im-
ages was slightly increased.
Intracellular metabolite extraction by cold methanol
(fingerprinting)
After incubating 50 ml E. coli cultures at OD600 = 0.6 with
different antibiotics at a concentration of 100 μM for
30 min, the total amount of 50 ml were collected on separ-
ate 0.22 μm filters [43]. Immediately after the disappearance
of the culture medium the unwashed filters were trans-
ferred to liquid nitrogen. Subsequently, each filter was
crushed into separate conical tubes and was suspended in
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5 ml of 100 % cold methanol which was cooled to below
−40 °C in a dry-ice-ethanol bath. Three freeze-thaw cycles
were applied to break the cell wall and to release the intra-
cellular metabolites. The lysates were centrifuged at 4000 g
for 15 min at 4 °C and the supernatants were transferred
into a clean tube. The metabolites were purified by adding
5 ml of water and 10 ml of chloroform and shaking for
5 min. The water–methanol phase contained the metabo-
lites and was separated from the lipophilic chloroform-
phase by centrifugation for 15 min at 4000 g. The metabol-
ite solution was transferred to a clean tube and two times
one milliliter was aliquoted into 1.5 ml-tubes. The samples
were dried down in a speed-vacuum evaporator, resus-
pended in 500 μl of D2O and stored at −20 °C until NMR
measurement.
Cultural supernatant (footprinting)
Samples for footprinting were prepared simultaneously to
intracellular metabolite extraction. After separating bacter-
ial cells by filtration the filtrate was stored at −20 °C until
NMR measurements.
NMR sample preparation
Samples for footprint and fingerprint-analysis were filtered
in 3-kDa-cutoff spin columns (3 K Nanosept: Omega;
VWR, Edmonton, Alberta, Canada) and filtered protein
was rinsed using additional 100 μl of D2O. Prior to use,
filters had been washed 5 times with water and then D2O
to remove the glycerol used to preserve the columns. A
final sample volume of 450 μl was transferred to clean
microfuge tubes. Samples were brought to a total volume
of 650 μl by addition of D2O, 40 μl of sodium azide (1 M
NaN3 solution) 140 μl of phosphate buffer (500 mM
NaH2PO buffer solution at pH 7.0) containing 2.5 mM of
2,2-dimethyl-2-silapentane-5-sulfonate (DSS) as internal
standard and the pH was adjusted to 7.00 ± 0.05.
NMR acquisition
All experiments were acquired on a Bruker AVANCE 600
spectrometer equipped with a 5 mm TXI probe (Bruker,
Milton, ON, Canada) at 298 K. The 1D 1H NMR spectra
were acquired using a standard Bruker 1D nuclear Over-
hauser enhancement spectroscopy (NOESY)-presaturation
pulse sequence (noesypr1d) [44, 45] in which the residual
water peak was irradiated during the relaxation delay of
1.0 s and during the mixing time of 100 ms. For an overall
recycle time of 5 s an acquisition time of 2 s and an initial
relaxation delay of 3 s was used. A total of 1024 scans were
collected for samples of culture experiments. All spectra
were acquired zero filled and Fourier transformed to 64 K
points. The obtained spectra were manually corrected for
phase and baseline distortions within Topspin (Bruker
Biospin, Ltd.) and were referenced to the DSS resonance at
0.0 ppm. Additionally, two-dimensional NMR experiments
such as total correlation spectroscopy (2D 1H-13C TOCSY)
and heteronuclear single quantum coherence spectroscopy
(2D 1H-13C HSQC) were performed for chemical shift as-
signments and verification.
Targeted metabolite profiling
1D 1H NMR spectra were imported into Chenomx NMR
Suite version 4.6 (Chenomx Inc., Edmonton, AB, Canada)
for metabolite identification and quantification by targeted
metabolite profiling analysis in the Profiler module which is
linked to a library representing over 260 metabolite entries
[46]. To determine the concentration of individual com-
pounds the concentration of DSS was used as reference.
Each compound concentration was then normalized to the
sum of all concentrations [47]. These normalized data were
then used for multivariate data analysis. Altogether 23
metabolites were profiled in bacterial fingerprints and 20
metabolites were identified in footprints.
Multivariate data analysis
For footprint and fingerprint analysis, 6 samples were
prepared respectively using three biological replicates and
two samples per replicate. Chemometric analysis was per-
formed using SIMCA-P version 11.5. A supervised projec-
tion technique (partial least-squares discriminant analysis,
PLS-DA) was applied where permutation validation sug-
gested that a reliable model could be built. Models were
optimized using leave-one-out cross-validation, compar-
ing the Q2 cross-validation estimate of accuracy with R2Y
training estimates of predictive power. A threshold im-
provement of 5 % in the Q2 metric was used as a cutoff
for significant components.
To reveal differences in the metabolomic profiles specific
to the antibiotic treatments, supervised PLS-DA modeling
was applied with binary contrast variables to indicate class-
membership for each treatment.
Prediction of antibiotic class membership
Because the ability of trained PLS-DA models to classify
novel antibiotics is of primary importance, a prediction
methodology was applied to three antibiotics (tetracycline,
streptomycin and carbenicillin) previously unseen in the
training process but whose mode of action was known a
priori from the literature (Table 1). A model, trained to
differentiate two antibiotics with different modes of action
(doxycycline, kanamycin) from control samples diluted with
H2O, was used to predict scores for the three alternate test
treatments. The distribution of predicted scores for test
samples was compared to that of each treatment in the
training dataset, for which SIMCA calculated membership
probabilities. The training class with the highest similarity,
and hence probability of membership, was taken to be the
predicted mode of action for each test treatment, and then
compared to the known expectation.
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